Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Princess Margaret Hospital and University of Toronto, Canada

Bookmark and Share

ESMO 33

12 - 16 Sep 2008
Published: 28 Nov 2008
Views: 15266
Rating:
Save
Prof. Ian Tannock
Blood pressure and efficacy in patients with metastatic renal cell carcinoma receiving axitinib, from ESMO 2008

Related Videos

Fundamental discoveries for prostate cancer in Sub-Saharan Africa: The MADCaP...
Dr Timothy Rebbeck - Harvard University and Dana-Farber Cancer Institute...
Fundamental discoveries for prostate cancer in Sub-Saharan Africa: The MADCaP network ( Dr Timothy Rebbeck - Harvard University and Dana-Farber Cancer Institute, Boston, USA )
21 Nov 2022
Top 10 choosing wisely genitourinary cancers
Dr Amandeep Arora - Tata memorial centre, Mumbai, India
Top 10 choosing wisely genitourinary cancers ( Dr Amandeep Arora - Tata memorial centre, Mumbai, India )
27 Oct 2022
Molecular profiling in prostate cancer: key challenges for clinical...
Dr Joaquin Mateo - Vall d’Hebron Institute of Oncology, Barcelona, Spain
Molecular profiling in prostate cancer: key challenges for clinical implementation ( Dr Joaquin Mateo - Vall d’Hebron Institute of Oncology, Barcelona, Spain )
24 Oct 2022
ESMO 2022: Best approaches to bladder preservation
Prof Morgan Rouprêt and Prof Nick James
ESMO 2022: Best approaches to bladder preservation ( Prof Morgan Rouprêt and Prof Nick James )
27 Sep 2022
Intraoperative Radiotherapy
Dr Mahima Pant - National Academy for Medical Sciences (NAMS), Kathmandu, Nepal
Intraoperative Radiotherapy ( Dr Mahima Pant - National Academy for Medical Sciences (NAMS), Kathmandu, Nepal )
25 Sep 2022
Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible...
Prof Jonathan E Rosenberg - Memorial Sloan Kettering Cancer Center, New York...
Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible locally advanced or metastatic urothelial cancer ( Prof Jonathan E Rosenberg - Memorial Sloan Kettering Cancer Center, New York City, USA )
14 Sep 2022
Updates in prostate cancer from ESMO 2022
Prof Eleni Efstathiou, Prof Gerhardt Attard and Prof Boris Hadaschik
Updates in prostate cancer from ESMO 2022 ( Prof Eleni Efstathiou, Prof Gerhardt Attard and Prof Boris Hadaschik )
12 Sep 2022
Latest in mRCC from ESMO 2022
Dr Javier Puente, Dr Bernard Escudier, Prof Viktor Grünwald and Prof Stéphane...
Latest in mRCC from ESMO 2022 ( Dr Javier Puente, Dr Bernard Escudier, Prof Viktor Grünwald and Prof Stéphane Oudard )
12 Sep 2022
ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer
Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike...
ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer ( Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike Schlürmann )
11 Sep 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation